Literature DB >> 8740229

Mechanism of increasing dystrophin-positive myofibers by myoblast transplantation: study using mdx/beta-galactosidase transgenic mice.

I Kinoshita1, J T Vilquin, J P Tremblay.   

Abstract

Female mdx/mdx mice were crossed with non-dystrophic transgenic males expressing the beta-galactosidase (beta-gal) gene under a muscle-specific promoter (TnILacZ1/29). All male offspring were mdx mice and about 50% of them also expressed the beta-gal gene. The beta-gal/mdx mice were selected as recipients for the transplantation of myoblasts from non-transgenic normal BALB/c mice. When host muscles were not irradiated before myoblast transplantation, 4.6% of the muscle fibers in host muscles were dystrophin positive 1 month after transplantation. Most of these dystrophin-positive muscle fibers were also beta-gal positive. About one quarter of these fibers are the result of reverse mutations; most of them have, however, been produced by fusion of donor myoblasts with host muscle fibers or with host myoblasts. The virtual absence of beta-gal-negative fibers indicates that there were no exclusively donor-donor fusions. When host muscles were irradiated before myoblast transplantation, roughly the same percentage (5.5%) of dystrophin-positive fibers were formed in the injected muscle, but 42% of them were beta-gal negative. These beta-gal-negative dystrophin-positive muscle fibers were formed by the exclusive fusion of donor myoblasts with one another rather than with host cells. This clearly indicates that myoblast transplantation can form completely new muscle fibers or muscle fiber segments when host satellite cell proliferation is reduced by irradiation. These newly formed muscle fibers had, however, a small diameter and additional myoblast transplantation may be required to increase their size. This situation has some similarities with findings in Duchenne muscular dystrophy patients of more than 6 years of age, who also have a limited proliferation capacity of their satellite cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740229     DOI: 10.1007/s004010050456

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  4 in total

1.  Laminin-111: a potential therapeutic agent for Duchenne muscular dystrophy.

Authors:  Sébastien Goudenege; Yann Lamarre; Nicolas Dumont; Joël Rousseau; Jérôme Frenette; Daniel Skuk; Jacques P Tremblay
Journal:  Mol Ther       Date:  2010-08-03       Impact factor: 11.454

2.  Intramuscular transplantation of human postnatal myoblasts generates functional donor-derived satellite cells.

Authors:  Daniel Skuk; Martin Paradis; Marlyne Goulet; Pierre Chapdelaine; David M Rothstein; Jacques P Tremblay
Journal:  Mol Ther       Date:  2010-07-06       Impact factor: 11.454

3.  An in vitro culture system that supports robust expansion and maintenance of in vivo engraftment capabilities for myogenic progenitor cells from adult mice.

Authors:  Zhan Wang; Daniel Cheung; Yu Zhou; Changjie Han; Colin Fennelly; Tracy Criswell; Shay Soker
Journal:  Biores Open Access       Date:  2014-06-01

4.  Myotubes Formed De Novo by Myoblasts Injected into the Scar of Myocardial Infarction Persisted for 16 Years in a Patient: Importance for Regenerative Medicine in Degenerative Myopathies.

Authors:  Daniel Skuk; Jacques P Tremblay
Journal:  Stem Cells Transl Med       Date:  2018-12-01       Impact factor: 6.940

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.